The largest database of trusted experimental protocols

Bleomycin blm

Manufactured by Nippon Kayaku
Sourced in Japan

Bleomycin (BLM) is a lab equipment product manufactured by Nippon Kayaku. It is a cytotoxic antibiotic agent used in research applications.

Automatically generated - may contain errors

6 protocols using bleomycin blm

1

Bleomycin-Induced Pulmonary Fibrosis in Mutyh Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Wild-type (C57BL/6J) mice were purchased from the Model Animal Research Center of Nanjing University. Mutyh+/− mice were previously established and backcrossed to C57BL/6J mice as described previously [15 (link)], and Mutyh−/− mice were obtained via inbreeding. Eight-week-old male mice (18-22 g) were used in the present experiment. All animals were maintained under standard conditions of 50% relative humidity, 21 ± 2°C, and a 12 h light cycle. To induce pulmonary fibrosis, 4 mg/kg bleomycin (BLM, Nippon Kayaku Co., Tokyo, Japan) was instilled intratracheally in a single dose, and an equal volume of normal saline (NS) was used as a control. The experimental mice were euthanized on days 7 (D7), 14 (D14), and 28 (D28) after intratracheal instillation. Lung tissues and serum from wild-type and Mutyh/ mice were collected for further analysis (Figure 1(a)). The animal experiments were performed based on the Jiangsu Provincial Experimental Animal Manage Committee under Contract 2011-0069, and the Experimental Animal Ethics Committee of Nanjing University approved the experimental protocols.
+ Open protocol
+ Expand
2

Bleomycin-induced Skin Fibrosis in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
For inducing skin fibrosis, the back skins of 8-week-old female BALB/c mice were shaved, and for 21 days, the mice were daily subcutaneously injected with 100 μg/100 μL bleomycin (BLM) (Nippon Kayaku, Tokyo, Japan) in sterile saline [33 (link)] (Additional file 1). The mASCs activated with LMWH (hep-mASCs) were cultured in DMEM/F-12 containing 10% FBS and 1.0% Pen-Strep supplemented with LMWH (10 and 100 μg/mL). In this study, to assess the effect of hep-mASCs, mice were assigned to the following groups, with n = 9 in each group: BLM-induced SSc (BLM-alone), BLM-induced SSc administered mASCs (BLM-mASC), BLM-induced SSc administered mASCs activated with 10 μg/mL LMWH (BLM-hep10-mASC), and BLM-induced SSc administered mASCs activated with 100 μg/mL LMWH (BLM-hep100-mASC). The mASCs cultured with or without LMWH were intravenously injected into the tail vein with 100 μL of PBS. In the BLM-alone group, 100 μL of PBS was intravenously injected into the tail vein. The number of administered cells was 2.5 × 104 cells. All three treatments were performed on day 7 following BLM administration. The mice were euthanised and their skins were harvested at 21 days after administering BLM.
+ Open protocol
+ Expand
3

Bleomycin-Induced Pulmonary Fibrosis Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Pulmonary fibrosis was induced by intratracheal instillation with bleomycin (BLM, 1.5 mg/kg, Nippon Kayaku, Japan) in 50 µl phosphate-buffered saline (PBS).
+ Open protocol
+ Expand
4

Bleomycin-Induced Lung Fibrosis Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
Six‐week‐old male C57BL/6 mice were purchased from Dae‐Han Laboratory Animal Research Co. (Daejeon, Korea) and housed at 50 ± 10% humidity and 22 ± 2°C with free access to sterile food and water. After acclimatization for 1 week, the mice were randomly distributed into experimental groups (n = 5). The mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), and then intratracheally administered an instillation of 100 mg/kg bleomycin (BLM; Nippon Kayaku Co.) through a 27‐gauge needle.19 IM‐1918 (2 mg/kg) or vehicle (0.1% dimethyl sulfoxide) was intraperitoneally injected every other day, starting on day 1 after BLM treatment. On day 14 after BLM administration, the mice were sacrificed, and the harvested lungs were subjected to immunohistochemical analysis and western blotting. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Korea Institute of Radiological and Medical Sciences.
+ Open protocol
+ Expand
5

Bleomycin-Induced Pulmonary Fibrosis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bleomycin (BLM) (Nippon Kayaku Co., Ltd, Takasaki-shi, Japan) was used to induce pulmonary fibrosis in mice [46 (link)]. Histochemical analysis was performed by Masson Trichrome staining to indicate the fibrosis. Ashcroft scores were used to indicate the degree of fibrosis [47 ]. The hydroxyproline in lung tissue was detected by using hydroxyproline microplate assay kit (abs580066, Absin, Shanghai, China). The mRNA expression levels of Col1a1, Timp1 and α-SMA in lung tissue were detected by using real-time PCR. There were six mice in each group.
+ Open protocol
+ Expand
6

Antifibrotic Effects of BM-MSCs Pretreated with rmG-CSF in Bleomycin-Induced Lung Fibrosis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female C57BL/6 mice were obtained from Jingda Laboratory Animal Company (Changsha, China). After being anaesthetized with pentobarbital sodium, the mice received an intratracheal injection of 50 μL of bleomycin (BLM) (3.5 mg/kg) (Nippon Kayaku, Japan) on day 0. To study the antifibrotic effects of BM-MSCs pretreated with rmG-CSF (PeproTech, USA), C57BL/6 mice were randomly assigned to one of the following groups: (1) control group, intratracheal saline plus tail vein injection of phosphate-buffered solution (PBS); (2) BLM group, intratracheal BLM plus tail vein injection of PBS; (3) BLM + rmG-CSF- (30 ng/mL) pretreated BM-MSC (1 × 105 in 100 μL) group, intratracheal BLM plus rmG-CSF-pretreated BM-MSC infusion into the tail vein; (4) BLM + rmG-CSF- (30 ng/mL) pretreated BM-MSC (3 × 105 in 100 μL) group; (5) BLM + rmG-CSF- (30 ng/mL) pretreated BM-MSC (1 × 106 in 100 μL) group; (6) BLM + BM-MSC (1 × 105 in 100 μL) group, intratracheal BLM plus BM-MSC infusion into the tail vein; (7) BLM + BM-MSC (3 × 105 in 100 μL) group; and (8) BLM + BM-MSC (1 × 106 in 100 μL) group. rmG-CSF-pretreated BM-MSCs and nontreated BM-MSCs were infused into the tail vein on day 14 after BLM injection, and lung tissues were harvested on day 21.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!